Idoxuridine

Summary

Idoxuridine (CHEMBL788) is an approved small-molecule antiviral drug (ATC D06BB01); indicated across 3 conditions including viral infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D06BB01 (+2 more)
• Indications: 3 conditions
• Clinical trials: 1
• Chemistry: 354.1 Da · C9H11IN2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL788
Name	Idoxuridine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5905
ChEBI	CHEBI:147675
ATC	D06BB01, J05AB02, S01AD01
Molecular formula	C9H11IN2O5
Molecular weight	354.1
InChIKey	XQFRJNBWHJMXHO-RRKCRQDMSA-N

SMILES: C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O

IUPAC name: 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione

ChEBI definition: A pyrimidine 2’-deoxyribonucleoside compound having 5-iodouracil as the nucleobase; used as an antiviral agent.

Pharmacological roles (ChEBI): antiviral drug, DNA synthesis inhibitor.

Also known as: 5IUDR, ALLERGAN-211, ALLERGAN211, Dendrid, Herplex, Idox, Idoxuridina, Idoxuridine, Idoxuridinum, Joddeoxiuridin, Kerecid, NSC-39661

Parent form; salt/anhydrous children: CHEMBL3967390

Patent coverage: 6,610 distinct patent families (24,732 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 24,729 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Thymidine kinase, cytosolic.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TK1	7.05	Ki	90	nM	CHEMBL_ACT_816583

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	4	MONDO:0005108	EFO:0000763
eye infectious disorder	4	MONDO:0043885	EFO:1001888
leukemia	2	MONDO:0005059	EFO:0000565

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003405	PHASE2	WITHDRAWN	Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).